USPTO Examiner FLICK JASON E - Art Unit 3783

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19022929RADIOPHARMACEUTICAL DELIVERY SYSTEM FOR PATIENT INFUSIONJanuary 2025May 2025Allow410NoNo
18985633Auto-InjectorDecember 2024March 2025Allow300NoNo
18985292Auto-InjectorDecember 2024March 2025Allow300NoNo
18986595Auto-InjectorDecember 2024March 2025Allow300NoNo
18983179Auto-InjectorDecember 2024April 2025Allow410NoNo
18982446Auto-InjectorDecember 2024April 2025Allow410NoNo
18982635Auto-InjectorDecember 2024April 2025Allow410NoNo
18819145RADIOPHARMACEUTICAL DELIVERY SYSTEM AND USE THEREOF FOR PATIENT INFUSIONAugust 2024December 2024Allow310NoNo
18779971INFUSION PUMP ASSEMBLY AND METHODJuly 2024May 2025Allow910NoNo
18653050TIME AVERAGED BASAL RATE OPTIMIZERMay 2024July 2024Allow200NoNo
18618798IMPROVED RADIOPHARMACEUTICAL DELIVERY SYSTEM AND USE THEREOF FOR PATIENT INFUSIONMarch 2024August 2024Allow400NoNo
18616200BLOOD REGURGITATION PREVENTING PUNCTURE AND GUIDANCE DEVICE WITHOUT SKIN DILATIONMarch 2024June 2024Allow300NoNo
18432297ANESTHETIC NERVE BLOCK AND METHODFebruary 2024April 2024Allow200NoNo
18399007SYSTEMS AND METHODS FOR DELIVERING A FLUID TO A PATIENT WITH REDUCED CONTAMINATIONDecember 2023June 2024Allow610NoNo
18489322PERITONSILLAR ABSCESS ASPIRATION KIT AND METHOD OF USEOctober 2023August 2024Allow1020YesNo
18374816METHODS, SYSTEMS, AND APPARATUS FOR ADMINISTERING AN ANTIBODY TREATMENT VIA INFUSIONSeptember 2023July 2024Allow1011NoNo
18367164TIME AVERAGED BASAL RATE OPTIMIZERSeptember 2023November 2023Allow210YesNo
18208858BRAIDED CATHETER ASSEMBLIESJune 2023February 2025Allow2000NoNo
18330785Acoustic Detection of a Usage of an Injection DeviceJune 2023April 2025Allow2240YesNo
18324510ELECTROSURGICAL SYSTEMMay 2023January 2025Allow2000NoNo
18254586CASSETTE FOR RETENTION OF FLUID PATH COMPONENTS FOR FLUID INJECTOR SYSTEMMay 2023March 2024Allow1010NoNo
18144555Auto-InjectorMay 2023August 2023Allow300NoNo
18144043ANESTHETIC NERVE BLOCK AND METHODMay 2023July 2023Allow200NoNo
18136278SYSTEMS AND METHODS FOR AUTOMATED INSULIN DELIVERY FOR DIABETES THERAPYApril 2023April 2025Allow2410NoNo
18100052PATCH-SIZED FLUID DELIVERY SYSTEMS AND METHODSJanuary 2023March 2025Allow2610NoNo
18064969Two-Stage Reconstituting InjectorDecember 2022May 2025Abandon2910YesNo
18048931FLUID INJECTOR SYSTEM VOLUME COMPENSATION SYSTEM AND METHODOctober 2022October 2024Allow2300NoNo
17937514SANITIZING CAPS FOR MEDICAL CONNECTORSOctober 2022June 2025Allow3210NoNo
17957396NASAL DRUG DELIVERY APPARATUS AND METHODS OF USESeptember 2022January 2025Allow2810NoNo
17902365INFUSION PUMP ALIGNMENT FEATURES FOR VERTICALLY-ORIENTATED IV TUBESSeptember 2022September 2024Allow2500NoNo
17820381SELF-ORIENTING SYRINGE AND SYRINGE INTERFACEAugust 2022June 2025Allow3400NoNo
17878832ANESTHESIA APPLICATORS/INJECTORS FOR DENTAL AND OTHER APPLICATIONS AND METHODS OF USEAugust 2022April 2025Abandon3210NoNo
17870761NASAL DEVICE WITH AIR FILTERJuly 2022May 2025Allow3410NoNo
17856253Auto-InjectorJuly 2022October 2022Allow300NoNo
17851608KEEP VEIN OPEN INFUSION FLOW CONTROL DEVICEJune 2022March 2025Allow3210NoNo
17788206CONNECTING DEVICEJune 2022May 2025Allow3500NoNo
17840423METHODS, SYSTEMS, AND APPARATUS FOR ADMINISTERING AN ANTIBODY TREATMENT VIA INFUSIONJune 2022June 2023Allow1211NoNo
17751020INTEGRATED MEDICAMENT DELIVERY DEVICE FOR USE WITH CONTINUOUS ANALYTE SENSORMay 2022April 2025Allow3510NoNo
17719441Auto-InjectorApril 2022February 2025Allow3410NoNo
17716991DEVICES AND METHODS FOR TREATING ACUTE KIDNEY INJURYApril 2022February 2025Abandon3410NoNo
17657612AMBULATORY MEDICAMENT PUMP VOICE OPERATIONMarch 2022October 2022Allow601NoNo
17655532INFUSION SYSTEM AND COMPONENTS THEREOFMarch 2022August 2024Allow2910NoNo
17698135MINIMALLY INVASIVE DERMAL ELECTROPORATION DEVICEMarch 2022November 2024Allow3210NoNo
17685170AMBULATORY MEDICAMENT DEVICE WITH POWER SAVING MODEMarch 2022September 2022Allow701NoNo
17653116AMBULATORY MEDICAMENT PUMP WITH SAFE ACCESS CONTROLMarch 2022June 2022Allow300NoNo
17673989BLADDER FOR AN INFUSION ASSEMBLYFebruary 2022September 2024Allow3110NoNo
17650747SYSTEMS AND METHODS FOR APPLYING MEDIA TO SKINFebruary 2022February 2023Allow1211NoNo
17650430Device for a Medicament ContainerFebruary 2022November 2024Allow3310NoNo
17589068METHODS, SYSTEMS, AND APPARATUS FOR ADMINISTERING A MONOCLONAL AND/OR POLYCLONAL ANTIBODY TREATMENT VIA RAPID INFUSIONJanuary 2022August 2023Allow1821YesNo
17549404INSULIN PUMP HAVING BASAL RATE TESTING FEATURESDecember 2021July 2024Allow3100NoNo
17454041MEDICAL DEVICES FOR FLUID DELIVERYNovember 2021May 2024Allow3000NoNo
17453801Electrically-Responsive HydrogelsNovember 2021May 2024Allow3100NoNo
17513487INTEGRATED INSULIN DELIVERY SYSTEM HAVING SAFETY FEATURES TO PREVENT HYPOGLYCEMIAOctober 2021November 2024Allow3710YesNo
17509638APPARATUS FOR PUMPING AND DIALYSISOctober 2021May 2024Abandon3120NoNo
17491949Multi-Cartridge Fluid Delivery DeviceOctober 2021January 2025Allow3910NoNo
17486784AMBULATORY MEDICAMENT DEVICE WITH SECURITY OVERRIDE PASSCODESeptember 2021June 2024Allow3310NoNo
17479305MULTI-CHANNEL AUTOMATIC PUMPSeptember 2021June 2023Allow2100NoNo
17476877Multi-Lumen Tamper TubeSeptember 2021December 2024Allow3930NoNo
17475202ENHANCED FLEXIBILITY NEUROVASCULAR CATHETERSeptember 2021September 2022Allow1220NoNo
17465653SYSTEMS AND METHODS FOR PROTECTING UMBILICAL STUMPSSeptember 2021October 2024Abandon3810NoNo
17445921SYSTEMS AND METHODS FOR APPLYING MEDIA TO SKINAugust 2021November 2021Allow200NoNo
17409228INTRAOCULAR IRRIGATOR-ASPIRATOR TIP COMPONENTAugust 2021November 2024Abandon3910NoNo
17405345SURGICAL TOOLAugust 2021March 2024Allow3000NoNo
17391446ALIGNMENT OF ELONGATED PARTICLES IN A PARTICLE DELIVERY DEVICEAugust 2021July 2024Allow3520NoNo
17426848MEDICAL DEVICE WITH ACTUATION MECHANISMJuly 2021August 2024Allow3710NoNo
17305894MEDICAL DEVICES FOR FLUID DELIVERYJuly 2021September 2021Allow200NoNo
17305507CONVERTIBLE PHACOEMULSIFICATION I/A SLEEVE AND MECHANICAL ACTIVATION MECHANISMJuly 2021February 2025Allow4320NoNo
17305508CONVERTIBLE PHACOEMULSIFICATION I/A SLEEVE AND MECHANICAL ACTIVATION MECHANISMJuly 2021November 2024Allow4010NoNo
17353379DEVICES, SYSTEMS, AND METHODS FOR PRE-HEATING FLUID TO BE INTRODUCED INTO A PATIENT DURING A SURGICAL PROCEDUREJune 2021February 2025Allow4400NoNo
17350554METHOD AND APPARATUS FOR DELIVERY OF CELL THERAPIESJune 2021January 2024Allow3100NoNo
17350853OVERMOLDED SEPTUMJune 2021March 2025Allow4511NoNo
17345720GRASPER FOR A NEEDLE SHEATH, CAP, AUTOINJECTOR AND METHOD OF PRODUCING A GRASPERJune 2021March 2025Allow4520YesNo
17330570SEPARABLE TWO-PART SINGLE LUMEN GAS SEALED ACCESS PORT FOR USE DURING ENDOSCOPIC SURGICAL PROCEDURESMay 2021October 2024Allow4130NoNo
17323529SYSTEMS AND METHODS FOR AUTOMATED INSULIN DELIVERY RESPONSE TO MEAL ANNOUNCEMENTSMay 2021June 2023Allow2500NoNo
17323056SEPARABLE TWO-PART SINGLE LUMEN GAS SEALED ACCESS PORT FOR USE DURING ENDOSCOPIC SURGICAL PROCEDURESMay 2021January 2024Allow3210NoNo
17306597METHOD AND APPARATUS FOR PERFORMING LAVAGE AND SUCTION AT A SURGICAL SITE IN A BODY LUMEN OR BODY CAVITYMay 2021April 2024Allow3500NoNo
17235919TAMPER EVIDENT ASSEMBLY WITH RFID FOR SYRINGESApril 2021May 2025Allow4821NoNo
17235724REAL TIME DRIP CHAMBER MONITORApril 2021June 2025Allow5021NoNo
17235909TAMPER EVIDENT CAP WITH RFID FOR SYRINGESApril 2021July 2024Allow3910NoNo
17285120SYSTEM AND METHOD FOR SUBSTANCE DELIVERYApril 2021September 2024Abandon4110NoNo
17224522PUMP SYSTEMApril 2021October 2023Abandon3110NoNo
17222562METHODS AND DEVICES TO PREVENT OBSTRUCTIONS IN MEDICAL TUBESApril 2021February 2024Allow3410NoNo
17222361MEDICAL DEVICES FOR FLUID DELIVERYApril 2021June 2021Allow200NoNo
17221976Patient Specific Guide Wire MethodApril 2021January 2024Allow3410NoNo
17213929GLUCOSE LEVEL CONTROL SYSTEM WITH CONTROL PARAMETER MODIFICATIONMarch 2021August 2023Allow2800NoNo
17194030GLUCOSE CONTROL SYSTEM WITH CONTROL PARAMETER MODIFICATIONMarch 2021July 2023Allow2800NoNo
17189162WEARABLE AUTOMATIC INJECTION DEVICE FOR CONTROLLED ADMINISTRATION OF THERAPEUTIC AGENTSMarch 2021October 2023Allow3210NoNo
17272360Cell Encapsulation Devices With Controlled Cell Bed ThicknessMarch 2021January 2025Allow4710NoNo
17186869WEARABLE INTRANASAL CLIP APPARATUS AND METHOD OF USEFebruary 2021September 2024Allow4220NoNo
17184829INFUSION PUMPSFebruary 2021June 2024Allow3920NoNo
17182693SYSTEMS AND METHODS FOR DELIVERY OF EXOSOMES VIA MRIFebruary 2021October 2023Allow3211NoNo
17180494WEARABLE INJECTOR WITH ADHESIVE SUBSTRATEFebruary 2021July 2022Allow1730NoNo
17174785METHODS AND SYSTEMS FOR CONTROLLING AN INFUSION PUMPFebruary 2021June 2025Allow5221NoNo
17161414Access Port and Catheter Assembly Including Catheter Distal Portion Stability FeaturesJanuary 2021April 2023Allow2700NoNo
17158358INTEGRATION OF INFUSION PUMP WITH REMOTE ELECTRONIC DEVICEJanuary 2021June 2023Allow2910NoNo
17152939Fluid Delivery Balloon Apparatus and Methods for UseJanuary 2021April 2024Allow3920NoNo
17151260EMERGENCY MEDICAL INTERVENTION DEVICEJanuary 2021August 2023Allow3010NoNo
17147047SURGICAL FLUID MANAGEMENT SYSTEMS AND METHODSJanuary 2021April 2024Allow3930NoNo
17144587ELECTROSURGICAL SYSTEMJanuary 2021January 2023Allow2500NoNo
17125009Fluid Management System and Method for Controlling Intracavity PressureDecember 2020March 2025Allow5120NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FLICK, JASON E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
5
Examiner Affirmed
4
(80.0%)
Examiner Reversed
1
(20.0%)
Reversal Percentile
32.7%
Lower than average

What This Means

With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
14
Allowed After Appeal Filing
5
(35.7%)
Not Allowed After Appeal Filing
9
(64.3%)
Filing Benefit Percentile
56.1%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 35.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner FLICK, JASON E - Prosecution Strategy Guide

Executive Summary

Examiner FLICK, JASON E works in Art Unit 3783 and has examined 457 patent applications in our dataset. With an allowance rate of 92.3%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner FLICK, JASON E's allowance rate of 92.3% places them in the 78% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by FLICK, JASON E receive 1.28 office actions before reaching final disposition. This places the examiner in the 24% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by FLICK, JASON E is 30 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +5.0% benefit to allowance rate for applications examined by FLICK, JASON E. This interview benefit is in the 29% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 38.1% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 45.0% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 76% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 68.8% of appeals filed. This is in the 49% percentile among all examiners. Of these withdrawals, 36.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 40.5% are granted (fully or in part). This grant rate is in the 40% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.7% of allowed cases (in the 63% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 42% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.